Physician profile
Lance J Lee
NPI 1699742189
$14,771.85
in general payments reported to CMS, 2019-2025
63 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,229 · 2020: $1,656 · 2021: $2,500 · 2022: $2,418 · 2023: $1,669 · 2024: $2,335 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,884 · Education: $84.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,883.69 |
| Education | $84.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,654.79 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Abbvie INC. | $989.35 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $751.74 | 2019-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $745.94 | 2019-2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $722.29 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $631.63 | 2020-2025 | Xcopri |
| Abbott Laboratories | $614.39 | 2019-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $602.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.19 | 2021-2024 | Andexxa, Wainua |
| Teva Pharmaceuticals USA, INC. | $478.22 | 2020-2025 | Austedo Xr, Austedo Xr |
| Medtronic, INC. | $474.23 | 2021-2025 | Linq II |
| Emd Serono, INC. | $441.33 | 2019-2023 | Mavenclad |
| Portola Pharmaceuticals, LLC | $399.05 | 2019-2020 | |
| Argenx US, INC. | $378.56 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $375.51 | 2019-2021 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $371.85 | 2019-2023 | Tysabri, Vumerity |
| Chiesi USA, INC. | $354.63 | 2020-2023 | Cleviprex |
| Viz.Ai, INC. | $335.14 | 2022 | |
| Depuy Synthes Sales INC. | $330.75 | 2019-2022 | |
| Lilly USA, LLC | $329.31 | 2019-2025 | Kisunla, Amyvid |
| Genentech USA, INC. | $267.04 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alnylam Pharmaceuticals INC. | $235.11 | 2022-2024 | Amvuttra |
| Neurocrine Biosciences, INC. | $211.44 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $210.07 | 2022-2025 | Rytary, Crexont |
| Eisai INC. | $188.56 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $160.42 | 2019-2020 | |
| Celgene Corporation | $138.88 | 2024-2025 | Zeposia |
| Janssen Scientific Affairs, LLC | $138.59 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $117.46 | 2021 | |
| Lundbeck LLC | $104.12 | 2024-2025 | Vyepti |
| Penumbra, INC. | $100.39 | 2024 | Penumbra System |
| Stryker Corporation | $100.01 | 2022-2023 | Trevo |
| E.R. Squibb & Sons, L.L.C. | $92.97 | 2020-2025 | |
| Mdd US Operations, LLC | $82.72 | 2022-2023 | Apokyn |
| Amgen INC. | $79.85 | 2019-2022 | |
| Genzyme Corporation | $71.81 | 2019 | |
| Kyowa Kirin, INC. | $70.93 | 2021-2024 | Nourianz |
| Avanir Pharmaceuticals, INC. | $69.47 | 2019-2020 | |
| Acorda Therapeutics, INC | $69.19 | 2019-2020 | |
| Forte Bio-Pharma LLC | $65.45 | 2025 | Tanlor |
| Boston Scientific Corporation | $62.65 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $57.17 | 2022 | |
| Ceribell, INC. | $54.98 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Imperative Care, INC | $54.55 | 2024 | Zoom 88-T Large Distal Platform |
| Pfizer INC. | $51.69 | 2024-2025 | |
| Livanova USA, INC. | $47.09 | 2019-2022 | |
| Resmed Corp | $46.96 | 2025 | |
| Horizon Therapeutics Plc | $45.53 | 2021-2023 | Uplizna |
| Medtronic USA, INC. | $31.74 | 2020 | |
| Tanabe Pharma America, INC. | $30.14 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $28.54 | 2024 | Nuedexta |
| Adamas Pharmaceuticals, INC. | $24.83 | 2020 | |
| Neurelis, INC. | $23.99 | 2023 | Valtoco |
| Janssen Biotech, INC. | $23.42 | 2025 | |
| Sunovion Pharmaceuticals INC. | $22.15 | 2021 | |
| Csl Behring | $20.63 | 2019 | |
| Medtronic Vascular, INC. | $20.38 | 2020 | |
| Ge Healthcare | $18.82 | 2023 | |
| Vertical Pharmaceuticals, LLC | $16.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.86 | 2025 | Caplyta |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.